219 related articles for article (PubMed ID: 1672268)
21. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
Jaspers C; Benker G; Reinwein D
Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
[TBL] [Abstract][Full Text] [Related]
22. Prolactinomas and resistance to dopamine agonists.
Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
[TBL] [Abstract][Full Text] [Related]
23. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
[TBL] [Abstract][Full Text] [Related]
24. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
25. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
26. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
Barrera CM; Ruiz AE; Banks WA
Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
[TBL] [Abstract][Full Text] [Related]
27. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
Vance ML; Lipper M; Klibanski A; Biller BM; Samaan NA; Molitch ME
Ann Intern Med; 1990 May; 112(9):668-73. PubMed ID: 1970714
[TBL] [Abstract][Full Text] [Related]
28. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
[TBL] [Abstract][Full Text] [Related]
29. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
31. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
32. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Homburg R; West C; Brownell J; Jacobs HS
Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
[TBL] [Abstract][Full Text] [Related]
33. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
34. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
Grebe SK; Delahunt JW; Feek CM
N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
[TBL] [Abstract][Full Text] [Related]
35. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
37. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
38. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
39. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
40. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]